SG11202011201QA - Fully human antibodies against ox40, method for preparing same, and use thereof - Google Patents

Fully human antibodies against ox40, method for preparing same, and use thereof

Info

Publication number
SG11202011201QA
SG11202011201QA SG11202011201QA SG11202011201QA SG11202011201QA SG 11202011201Q A SG11202011201Q A SG 11202011201QA SG 11202011201Q A SG11202011201Q A SG 11202011201QA SG 11202011201Q A SG11202011201Q A SG 11202011201QA SG 11202011201Q A SG11202011201Q A SG 11202011201QA
Authority
SG
Singapore
Prior art keywords
human antibodies
antibodies against
fully human
preparing same
preparing
Prior art date
Application number
SG11202011201QA
Other languages
English (en)
Inventor
Yong Zheng
Baotian Yang
Jing Li
Original Assignee
Wuxi Biologics Shanghai Co Ltd
Wuxi Biologics Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Shanghai Co Ltd, Wuxi Biologics Ireland Ltd filed Critical Wuxi Biologics Shanghai Co Ltd
Publication of SG11202011201QA publication Critical patent/SG11202011201QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202011201QA 2018-05-11 2019-05-07 Fully human antibodies against ox40, method for preparing same, and use thereof SG11202011201QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018086574 2018-05-11
CN201810529840 2018-05-29
PCT/CN2019/085886 WO2019214624A1 (en) 2018-05-11 2019-05-07 Fully human antibodies against ox40, method for preparing same, and use thereof

Publications (1)

Publication Number Publication Date
SG11202011201QA true SG11202011201QA (en) 2020-12-30

Family

ID=68466901

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011201QA SG11202011201QA (en) 2018-05-11 2019-05-07 Fully human antibodies against ox40, method for preparing same, and use thereof

Country Status (12)

Country Link
US (1) US20210171647A1 (es)
EP (2) EP3790903A4 (es)
JP (1) JP7411575B2 (es)
KR (1) KR20210039986A (es)
CN (2) CN114685665A (es)
AU (1) AU2019264712A1 (es)
BR (1) BR112020023026A2 (es)
CA (1) CA3103040A1 (es)
MX (1) MX2020012081A (es)
SG (1) SG11202011201QA (es)
TW (1) TWI831778B (es)
WO (1) WO2019214624A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230022859A1 (en) * 2019-11-21 2023-01-26 Beigene, Ltd. Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors
CN113045655A (zh) * 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
CN113045654A (zh) * 2019-12-27 2021-06-29 南开大学 抗ox40抗体及其用途
CN111153994B (zh) * 2019-12-31 2021-10-15 武汉班科生物技术股份有限公司 人肿瘤坏死因子的人源单克隆抗体
CN113429483A (zh) * 2020-03-23 2021-09-24 百奥泰生物制药股份有限公司 一种免疫细胞激活剂的开发及应用
CN113527482B (zh) * 2020-04-17 2023-07-21 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN111518209B (zh) * 2020-05-09 2023-07-25 郑州航空港百桥生物科技有限公司 特异性结合人ox40的单克隆抗体及其应用
CN116490209A (zh) * 2020-11-12 2023-07-25 同润生物医药(上海)有限公司 联合疗法及其使用方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
DE60317677T2 (de) 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
CN101918447B (zh) 2007-12-14 2014-06-11 布里斯托尔-米尔斯·斯奎布公司 人ox40受体的结合分子
SG187945A1 (en) * 2010-08-23 2013-03-28 Univ Texas Anti-ox40 antibodies and methods of using the same
WO2013008171A1 (en) * 2011-07-11 2013-01-17 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
AU2013358958B2 (en) 2012-12-14 2018-09-20 Open Monoclonal Technology, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
PE20160690A1 (es) 2013-03-18 2016-08-14 Biocerox Prod Bv Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
WO2015015401A2 (en) * 2013-08-02 2015-02-05 Pfizer Inc. Anti-cxcr4 antibodies and antibody-drug conjugates
PE20161571A1 (es) * 2014-03-31 2017-02-07 Genentech Inc Anticuerpos anti-ox40 y metodos de uso
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
WO2016179517A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
WO2016185016A1 (en) * 2015-05-21 2016-11-24 Alligator Bioscience Ab Novel polypeptides
BR112017025191A2 (pt) * 2015-05-29 2018-07-31 Bristol-Myers Squibb Company anticorpos contra ox40 e uso dos mesmos
CN108137684B (zh) 2015-10-15 2022-03-08 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
EP3383914A4 (en) * 2015-12-02 2019-10-30 Agenus Inc. ANTI-OX40 ANTIBODIES AND METHODS OF USE
US10669344B2 (en) * 2016-08-12 2020-06-02 Janssen Biotech, Inc. Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
CN107815465B (zh) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用

Also Published As

Publication number Publication date
AU2019264712A1 (en) 2021-01-07
JP2021522847A (ja) 2021-09-02
TW202003575A (zh) 2020-01-16
KR20210039986A (ko) 2021-04-12
CN110467674B (zh) 2022-05-31
TWI831778B (zh) 2024-02-11
WO2019214624A1 (en) 2019-11-14
CN114685665A (zh) 2022-07-01
CA3103040A1 (en) 2019-11-14
EP4074732A1 (en) 2022-10-19
BR112020023026A2 (pt) 2021-02-09
EP3790903A4 (en) 2022-06-08
MX2020012081A (es) 2021-04-28
JP7411575B2 (ja) 2024-01-11
US20210171647A1 (en) 2021-06-10
EP3790903A1 (en) 2021-03-17
CN110467674A (zh) 2019-11-19

Similar Documents

Publication Publication Date Title
SG11202011201QA (en) Fully human antibodies against ox40, method for preparing same, and use thereof
SG11202003782XA (en) Triple-chain antibody, method for preparation and use thereof
ZA202001447B (en) M-diamide compound and preparation method therefor and use thereof
EP3664762A4 (en) SURGICAL FRAME WITH TORSO SLING AND METHOD OF USING THEREOF
EP3689909A4 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
HUE054964T2 (hu) Pirazol-heteroaril készítmény, az elõállítás módja és gyógyászati felhasználása
EP4042881A4 (en) MICROCAPSULE, PREPARATION METHOD AND ASSOCIATED APPLICATION
SG11202009962UA (en) Bcma-targeted chimeric antigen receptor as well as preparation method therefor and application thereof
IL268704B (en) Formulations of antibodies against human rankl, and methods of using them
EP3708582A4 (en) 4-1BB ANTIBODIES AND THE MANUFACTURING METHOD AND USES THEREOF
EP3632907C0 (en) N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
HK1258545A1 (zh) 一種脲類化合物、其製備方法及其醫藥用途
IL272446A (en) Penta-condensed hexa-heterocyclic compounds, method for their preparation, drug combination and use thereof
HK1258007A1 (zh) 抗人程序性死亡受體1抗體及其製備方法和用途
EP3589670A4 (en) ELASTOMER, ITS PREPARATION PROCESS AND ASSOCIATED USE
EP3822290A4 (en) SEMA4D ANTIBODY, METHOD FOR ITS PRODUCTION AND ITS USE
EP3395834A4 (en) ANTI-TPBG ANTIBODIES AND ITS PREPARATION METHOD, CONJUGATED AND USE THEREOF
EP3773720A4 (en) MONOCLONAL ANTIBODY AGAINST HUMAN 4-1BB, ITS PREPARATION PROCESS, AND ITS USE
SG11202004292PA (en) Medicine for tissue regeneration, and preparation method therefor
EP3730620A4 (en) CROSS-IMMUNIZATION ANTIGENIC VACCINE AND PROCESS FOR PREPARATION
GB202008327D0 (en) Method for preparing 2,2'dipyridine and derivatives thereof
SI3269735T1 (sl) Protitelo proti sklerostinu, antigen-vezavni fragment in medicinska uporaba le-tega
GB201904104D0 (en) Composition, method and use
EP3589350A4 (en) MEDICAL DEVICE, PROCESS FOR ITS PREPARATION, AND ITS USE
EP3758751A4 (en) MONOCLONAL ANTIBODIES AGAINST HUMAN LAG-3, METHOD OF MANUFACTURING AND USING THEREOF